DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for carcinoma of supraglottis — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCarcinoma of supraglottis maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for carcinoma of supraglottis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
tumor protein p53 (TP53) — TP53 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9R2Q · 3.2 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
In a 2000 study of 13 supraglottic carcinomas, neoplastic cells expressed alpha2beta1, alpha3beta1, alpha4beta1, alpha5beta1 and alpha6beta1 integrins, while normal and metaplastic epithelium was alpha5beta1 negative. TGFbeta1 and IFNgamma gene expression was observed in the majority of tumours. The authors proposed that TGFbeta1-driven upregulation of alpha2beta1, alpha5beta1 and tenascin in neoplastic cells might represent an immune-related process that helps tumour growth and progression. No drug was tested, and no survival data were reported.
A 2011 cross-sectional study of 50 patients (45 male, 5 female, aged 40–80) found that 40% had regional lymph node involvement at presentation. Level-II nodes were most frequently involved, and homolateral involvement occurred in 84.21% of node-positive cases. The commonest presenting symptoms were cough and irritation (90%), dysphagia (76%) and change of voice (72%). 80% of patients had T2 tumours, and the most common overall stage was stage III (40%) followed by stage II (24%). Smoking was reported in 70% of patients. No treatment outcomes or survival data were given.
A 2017 study of 123 supraglottic carcinoma cases treated between 1999 and 2015 examined clinical features by subsite (arytenoid, false vocal cord, infrahyoid epiglottis, epiglottis, aryepiglottic fold). The abstract states that associations between subsite and age, primary symptoms, tumour stage and disease-specific survival were investigated, but no numerical results, survival rates or response data are provided in the available text. No drug intervention is mentioned.
What is missing from the available evidence is any controlled trial of a drug for supraglottic carcinoma, any survival or response-rate data from a treatment study, and any molecular or clinical stratification that could guide patient selection for a repurposing strategy. The 2000 study offers a candidate mechanism (TGFbeta1 signalling and integrin expression) but no therapeutic test. The two clinical studies describe presentation patterns and nodal spread but do not report outcomes after any specific intervention. Funding for a prospective trial, a defined repurposing candidate, and a design that accounts for subsite and nodal status are all absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Head & Neck · 2000 · 16 citations
?5 Integrin distribution and TGF?1 gene expression in supraglottic carcinoma: Their role in neoplastic local invasion and metastasis
AbstractBACKGROUND: Head and neck carcinomas are characterized by tumor-infiltrating lymphocytes (TIL) producing cytokines. Adhesion molecules, extracellular matrix proteins (ECMPs), and cytokines regulate cell-cell and cell-ECMPs interactions. We investigated the distribution of these proteins to contribute to better understanding of their role in local tumor invasion and metastasis. METHODS: Distribution of integrins, laminin, type IV collagen, tenascin, and fibronectin was immunohistochemically evaluated in 13 supraglottis carcinomas. Cytokines gene expression was assessed by reverse-transcriptase-polymerase chain reaction (RT-PCR). RESULTS: Neoplastic cells were alpha2beta1, alpha3beta1, alpha4beta1, alpha5beta1 and alpha6beta1 positive. Normal and metaplastic epithelium was alpha5beta1 negative; the stroma of primary and metastatic tumors was tenascin and fibronectin positive. TGFbeta1 and IFNgamma gene expression was observed in the majority of tumors. CONCLUSIONS: Because TGFbeta1 is known to down-modulate immune processes and to increase alpha2beta1, alpha5beta1, and tenascin distribution, we propose that their expression in neoplastic cells of supraglottis carcinoma might represent an immune-related process able to help tumor growth and progression.
Bangladesh Journal of Otorhinolaryngology · 1970 · 1 citations · open access
Pattern of lymph node metastasis in supraglottic carcinoma
AbstractObjectives: To find out the frequency and distribution of lymph node metastasis in supraglottic carcinoma. Study Design: Cross sectional study. Methods: 50 cases are included in this study (male-45 and female-5) between the ages of 40- 80 years who were treated from September 2007 to February 2008. Study based on history, clinical, radiological, laboratory and histopathological examination. Results: Highest number of patients was in the age group 50-60 years. Male and female ratio was 9:1. Commonest occupational group was cultivators and most patients come from poor socio-economic class. Smoking was commonest (70%).Out of 50 patients 20 (40%) had their regional lymph node involved. Level-II lymph nodes were involved in higher number of cases. Nodes in advanced stage of involvement were found in most cases. Homolateral involvement of nodes was in most cases (84.21%). Most of the patients present with more than one symptom and the commonest presenting symptoms of supraglottic carcinoma was cough and irritation (90%) followed by dysphagia (76%) and change of voice (72%). Most of the supraglottic growth was exophytic in appearance. The common site involve (50%) in the study were aryepiglottic fold and arytenoids. 80% of patients were present with T2 tumours. Patients were staged according to the TNM feature. Most of the patients (40%) were in stage-III followed by stage-II (24%). Conclusion: Lymphadenopathy is present much higher frequency in supraglottic carcinoma than glottic carcinoma. Key words: Supraglottic Carcinoma; Lymph node DOI: http://dx.doi.org/10.3329/bjo.v17i2.8850 BJO 2011; 17(2): 110-116
Koutou (THE LARYNX JAPAN) · 2017 · 0 citations · open access
The Clinical Features According to the Subsites of Supraglottic Carcinoma
AbstractPurpose : We investigated the clinical features according to the subsites of supraglottic carcinoma. Patients and Methods : We investigated 123 cases of supraglottic carcinoma treated that were at Osaka Medical College from 1999 to 2015. The cases involved five subsites: the arytenoid, false vocal cord, infrahyoid epiglottis, epiglottis, and the aryepiglottic fold. We investigated the associations between the subsites and characteristics of the patients, including age, primary symptoms, tumor stage and disease-specific survival.
Greater South Information System · 1970 · 0 citations · open access
Pattern of lymph node metastasis in supraglottic carcinoma
AbstractObjectives: To find out the frequency and distribution of lymph node metastasis in supraglottic carcinoma. Study Design: Cross sectional study. Methods: 50 cases are included in this study (male-45 and female-5) between the ages of 40- 80 years who were treated from September 2007 to February 2008. Study based on history, clinical, radiological, laboratory and histopathological examination. Results: Highest number of patients was in the age group 50-60 years. Male and female ratio was 9:1. Commonest occupational group was cultivators and most patients come from poor socio-economic class. Smoking was commonest (70%).Out of 50 patients 20 (40%) had their regional lymph node involved. Level-II lymph nodes were involved in higher number of cases. Nodes in advanced stage of involvement were found in most cases. Homolateral involvement of nodes was in most cases (84.21%). Most of the patients present with more than one symptom and the commonest presenting symptoms of supraglottic carcinoma was cough and irritation (90%) followed by dysphagia (76%) and change of voice (72%). Most of the supraglottic growth was exophytic in appearance. The common site involve (50%) in the study were aryepiglottic fold and arytenoids. 80% of patients were present with T2 tumours. Patients were staged according to the TNM feature. Most of the patients (40%) were in stage-III followed by stage-II (24%). Conclusion: Lymphadenopathy is present much higher frequency in supraglottic carcinoma than glottic carcinoma. Key words: Supraglottic Carcinoma; Lymph node DOI: http://dx.doi.org/10.3329/bjo.v17i2.8850 BJO 2011; 17(2): 110-116
Greater South Information System · 1970 · 0 citations · open access
Pattern of lymph node metastasis in supraglottic carcinoma
AbstractObjectives: To find out the frequency and distribution of lymph node metastasis in supraglottic carcinoma. Study Design: Cross sectional study. Methods: 50 cases are included in this study (male-45 and female-5) between the ages of 40- 80 years who were treated from September 2007 to February 2008. Study based on history, clinical, radiological, laboratory and histopathological examination. Results: Highest number of patients was in the age group 50-60 years. Male and female ratio was 9:1. Commonest occupational group was cultivators and most patients come from poor socio-economic class. Smoking was commonest (70%).Out of 50 patients 20 (40%) had their regional lymph node involved. Level-II lymph nodes were involved in higher number of cases. Nodes in advanced stage of involvement were found in most cases. Homolateral involvement of nodes was in most cases (84.21%). Most of the patients present with more than one symptom and the commonest presenting symptoms of supraglottic carcinoma was cough and irritation (90%) followed by dysphagia (76%) and change of voice (72%). Most of the supraglottic growth was exophytic in appearance. The common site involve (50%) in the study were aryepiglottic fold and arytenoids. 80% of patients were present with T2 tumours. Patients were staged according to the TNM feature. Most of the patients (40%) were in stage-III followed by stage-II (24%). Conclusion: Lymphadenopathy is present much higher frequency in supraglottic carcinoma than glottic carcinoma. Key words: Supraglottic Carcinoma; Lymph node DOI: http://dx.doi.org/10.3329/bjo.v17i2.8850 BJO 2011; 17(2): 110-116
Archives of Otolaryngology - Head and Neck Surgery · 1987 · 0 citations
Therapies for Supraglottic Carcinoma
AbstractJames Bartels, MD, and colleagues from the University of Rochester (NY) presented their work on the different therapies for supraglottic carcinoma at the Eastern Section Meeting of the Triological Society. This was a retrospective study of 1104 patients with squamous cell carcinoma of the supraglottis treated from 1970 to 1982. In general, the patients with T1 and T2 lesions were treated with surgery or radiation therapy. Patients with T3 and T4 lesions, who comprised most of the study group, were generally treated with surgery and radiation therapy. In the T2 group, 44% of the patients survived for three years with primary radiation therapy and subsequent salvage surgery, whereas 77% survived for three years with surgery combined with planned radiation therapy. In patients with T2, NO or T2, N1 lesions, there was a 64% recurrence rate with radiation therapy and a 35% recurrence rate with surgery. The patients whose lesions recurred
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
